Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
Inv. presentation
Credit agrmnt [a]
Acq. announced
Director departure
Appointed director
Employment agrmnt
|
|
AMAG PHARMACEUTICALS, INC. (AMAG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/14/2020 |
GN
| AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration's Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) |
| 10/30/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Eaton Vance Corp., MobileIron, Inc., and Seacoast Commerce Banc Holdings |
| 10/15/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of AMAG Pharmaceuticals, Inc. Buyout |
| 10/15/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), MobileIron, Inc. (NASDAQ GS: MOBL), Seacoast Commerce Banc Holdings (OTC: SCBH), and Perceptron, Inc. (NASDAQ GS: PRCP) |
| 10/14/2020 |
GN
| AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients |
| 10/07/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., MobileIron, Inc., Monaker Group, Inc., and Seacoast Commerce Banc Holdings |
| 10/05/2020 |
GN
| AMAG Pharmaceuticals Provides Update on FDA's Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection) |
| 10/01/2020 |
GN
| Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals |
| 07/27/2020 |
GN
| AMAG Pharmaceuticals Completes Divestment of Women's Health Assets |
| 07/23/2020 |
GN
| AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand |
| 06/11/2020 |
GN
| AMAG Pharmaceuticals Announces Leadership Changes |
| 05/27/2020 |
GN
| AMAG Pharmaceuticals to Participate in Jefferies Virtual Global Healthcare Conference |
| 05/21/2020 |
GN
| AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent Pharma for up to $125 Million |
| 04/16/2020 |
GN
| AMAG Pharmaceuticals Provides COVID-19 Company Update |
| 03/04/2020 |
GN
| AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update |
| 02/14/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG |
| 01/27/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG |
| 01/09/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims??On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG |
| 01/09/2020 |
GN
| AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update |
| 01/03/2020 |
GN
| AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference |
| 11/13/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG |
| 11/01/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG |
| 10/29/2019 |
GN
| AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection) |
| 10/29/2019 |
GN
| AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial |
| 10/25/2019 |
GN
| AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology |
| 10/24/2019 |
GN
| AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET |
| 10/11/2019 |
GN
| AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & Gynecology |
| 09/05/2019 |
GN
| AMAG Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference |
| 09/04/2019 |
GN
| AMAG Urges Stockholders to Take No Action on Caligan Partners' Consent Solicitation Materials |
| 08/27/2019 |
GN
| AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection) |
| 08/20/2019 |
GN
| AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4) |
| 07/29/2019 |
GN
| AMAG Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, August 7, 2019 at 8:00 a.m. ET |
| 06/21/2019 |
GN
| AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women |
| 05/17/2019 |
GN
| AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York |
|
|
|